Press release
Nonalcoholic Steatohepatitis (NASH) Patient Pool Market to Surge to USD 26.4 Billion by 2034
Nonalcoholic Steatohepatitis
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71159
NASH has become one of the most urgent public health challenges worldwide, largely driven by the global obesity epidemic, rising diabetes prevalence, and sedentary lifestyles. Despite its rising burden, there are currently no FDA-approved therapies, making it one of the most competitive and innovative pharmaceutical markets under development. The next decade will witness rapid advances in drug approvals, biomarker-driven diagnostics, and personalized care approaches.
Market Overview
• Market Size (2024): USD 6.8 billion
• Forecast (2034): USD 26.4 billion
• CAGR (2025-2034): 14.5%
The NASH market is expected to grow at an exceptional pace due to increasing patient numbers, the imminent launch of novel therapies, and significant investment from pharmaceutical companies. Lifestyle interventions remain critical, but drug innovation will dominate future growth.
Key Highlights:
• Rising prevalence of obesity, diabetes, and metabolic syndrome driving NASH incidence.
• Strong pipeline of therapies targeting metabolic, anti-fibrotic, and anti-inflammatory pathways.
• Growing adoption of non-invasive diagnostic tools (imaging, biomarkers).
• Increasing government and payer focus on reducing the long-term burden of liver disease.
Segmentation Analysis
By Product Type:
• Pipeline Therapies
o FXR Agonists (Obeticholic Acid, Cilofexor)
o PPAR Agonists (Elafibranor, Lanifibranor)
o GLP-1 Receptor Agonists (Semaglutide)
o THR-β Agonists (Resmetirom)
o Others (anti-fibrotics, immunotherapies)
• Lifestyle & Nutritional Interventions
• Supportive Therapies
By Platform:
• Small Molecules
• Biologics
• Combination Therapies
By Technology:
• Imaging (MRI, FibroScan, Ultrasound Elastography)
• Biomarker-Based Diagnostics
• Clinical Research & Drug Development Platforms
By End Use:
• Hospitals
• Specialty Clinics
• Research Institutes
• Retail & Online Pharmacies
By Application:
• Fibrosis Stage 1-2
• Advanced Fibrosis Stage 3-4
• Cirrhosis Management
• Clinical Trials
Segmentation Summary:
While lifestyle interventions dominate current management, pipeline drugs - particularly FXR, PPAR, GLP-1, and THR-β agonists - are expected to reshape treatment. Hospitals and specialty clinics remain central due to complex diagnostic and monitoring requirements, while research institutes continue to drive drug discovery and biomarker innovation.
Explore Full Report here: https://exactitudeconsultancy.com/reports/71159/nonalcoholic-steatohepatitis-market
Regional Analysis
North America
• Largest market with ~46% share in 2024.
• High obesity and diabetes prevalence underpin demand.
• U.S. leads in clinical trial activity and potential early drug approvals.
Europe
• Holds ~27% share.
• Germany, UK, and France are key markets with strong R&D activity.
• Governments are expanding focus on liver disease prevention.
Asia-Pacific
• Fastest-growing region with CAGR of ~16%.
• Rising obesity and diabetes prevalence in China, India, and Japan.
• Expanding healthcare infrastructure and clinical trial networks.
Middle East & Africa
• Smaller market share, but growing prevalence of metabolic syndrome is increasing demand.
• Access barriers limit advanced diagnostic and treatment adoption.
Latin America
• Brazil and Mexico drive demand with rising obesity-related liver disease.
• Expanding pharmaceutical access and urban healthcare centers support growth.
Regional Summary:
North America leads due to strong infrastructure and pipeline adoption, while Asia-Pacific will show the fastest growth, fueled by a rapidly expanding patient pool and clinical trial participation.
Market Dynamics
Key Growth Drivers:
• Rising global obesity and type 2 diabetes epidemics.
• Expanding pipeline with multiple late-stage drug candidates.
• Increasing adoption of non-invasive diagnostic technologies.
• Strong investments from major pharmaceutical companies.
Key Challenges:
• Lack of currently approved therapies.
• High R&D costs and late-stage trial failures.
• Difficulty in patient recruitment due to need for biopsies in trials.
• Limited awareness in emerging regions.
Latest Trends:
• Breakthrough designation for drugs like Resmetirom and Obeticholic Acid.
• Growing role of GLP-1 receptor agonists (e.g., semaglutide) in combination approaches.
• AI-driven imaging and biomarker tools for faster, non-invasive diagnosis.
• Expansion of combination therapy strategies targeting metabolic and fibrotic pathways.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71159
Competitor Analysis
Major Players in the Market:
• Madrigal Pharmaceuticals (Resmetirom)
• Intercept Pharmaceuticals (Obeticholic Acid)
• Genfit (Elafibranor)
• Novo Nordisk (Semaglutide)
• Inventiva Pharma (Lanifibranor)
• Gilead Sciences, Inc.
• Novartis AG
• Pfizer Inc.
• Bristol Myers Squibb (BMS)
• AstraZeneca plc
Competitive Summary:
Madrigal and Intercept are leading the late-stage pipeline race, while Novo Nordisk's GLP-1 receptor agonists are showing strong cross-therapeutic potential. Gilead and Novartis are investing heavily in combination regimens, while smaller biotech firms like Inventiva and Genfit are innovating niche molecules. Competition is intensifying, with multiple Phase 3 readouts expected to shape the market before 2030.
Conclusion
The Nonalcoholic Steatohepatitis (NASH) Market, valued at USD 6.8 billion in 2024, is projected to reach USD 26.4 billion by 2034, growing at a CAGR of 14.5%. This makes NASH one of the fastest-growing therapeutic markets in hepatology and metabolic disorders.
Key Takeaways:
• NASH growth is driven by obesity, diabetes, and lifestyle-related risk factors.
• Pipeline therapies, particularly FXR, PPAR, GLP-1, and THR-β agonists, will dominate future care.
• North America leads, but Asia-Pacific shows the strongest growth trajectory.
• Drug approvals between 2025 and 2030 will be pivotal in reshaping competitive dynamics.
The next decade will mark a turning point for NASH, transitioning from lifestyle and supportive care to targeted, disease-modifying pharmacotherapies, creating enormous opportunities for pharmaceutical innovators and healthcare providers.
This report is also available in the following languages : Japanese (非アルコール性脂肪肝炎市場), Korean (비알코올성 지방간염 시장), Chinese (非酒精性脂肪性肝炎市场), French (Marché de la stéatohépatite non alcoolique), German (Markt für nichtalkoholische Steatohepatitis), and Italian (Mercato della steatoepatite non alcolica), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/71159/nonalcoholic-steatohepatitis-market#request-a-sample
Our More Reports:
Ichthyosis Market
https://exactitudeconsultancy.com/reports/71419/ichthyosis-market
Keloid Market
https://exactitudeconsultancy.com/reports/71421/keloid-market
Mastocytosis Market
https://exactitudeconsultancy.com/reports/71423/mastocytosis-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Nonalcoholic Steatohepatitis (NASH) Patient Pool Market to Surge to USD 26.4 Billion by 2034 here
News-ID: 4159982 • Views: …
More Releases from Exactitude Consultancy
Hypertrophic Cardiomyopathy Market to Reach USD 3.21 Billion by 2034, Growing at …
Introduction
Hypertrophic cardiomyopathy (HCM) is a genetic heart disorder characterized by abnormal thickening of the heart muscle, which can impair blood flow and increase the risk of arrhythmias, heart failure, and sudden cardiac death. Once managed primarily through beta-blockers, calcium channel blockers, and invasive procedures, the HCM treatment landscape has expanded with the approval of targeted therapies such as cardiac myosin inhibitors.
Growing awareness of genetic cardiovascular diseases, advances in molecular diagnostics,…
Biologics Contract Research Organization (CRO) Market to Reach USD 37.9 Billion …
Introduction
Biologics-including monoclonal antibodies, vaccines, recombinant proteins, and advanced therapies-are at the forefront of modern medicine. Their development, however, requires significant expertise, advanced infrastructure, and compliance with stringent regulatory standards. To meet these demands, pharmaceutical and biotechnology companies are increasingly outsourcing to Contract Research Organizations (CROs) specializing in biologics.
Biologics CROs provide services spanning discovery, preclinical research, clinical trials, bioanalytical testing, and regulatory consulting. With the rise of biologics, biosimilars, and advanced…
Niemann-Pick Disease Market to Reach USD 1.02 Billion by 2034, Growing at 10.6% …
Introduction
Niemann-Pick disease (NPD) is a group of rare, inherited lysosomal storage disorders caused by mutations that disrupt lipid metabolism, leading to progressive neurological decline, organ dysfunction, and premature death. The condition is categorized into several subtypes (A, B, and C), each varying in severity and progression.
Historically, treatment has been limited to palliative and supportive care. However, the landscape is changing rapidly with the development of enzyme replacement therapies (ERT), substrate…
PERK Inhibitors Market Forecast: USD 3.2 Billion by 2034 | Major Participants: N …
The fight against cancer and neurodegenerative diseases has brought the spotlight on the PERK (Protein kinase RNA-like endoplasmic reticulum kinase) pathway, a critical regulator of the unfolded protein response. PERK inhibitors are designed to modulate this pathway, reducing stress-induced cell death and playing a pivotal role in oncology, neurodegenerative research, and metabolic disorders. As precision medicine continues to gain traction, PERK inhibitors are attracting significant attention from both biotech firms…
More Releases for NASH
The Growing Demand For NASH Treatment Amid Obesity Epidemic: A Key Catalyst Acce …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Non-Alcoholic Steatohepatitis (NASH) Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for non-alcoholic steatohepatitis (NASH) has seen a considerable expansion in the past few years. Its value is expected to rise from $4.5 billion in 2024 to $6.06 billion in 2025, marking…
Nonalcoholic Steatohepatitis (NASH) Market Massive Growth opportunity Ahead
Introduction
Nonalcoholic Steatohepatitis (NASH) is an advanced form of nonalcoholic fatty liver disease (NAFLD) characterized by fat accumulation in the liver along with inflammation and liver cell damage. If left untreated, NASH can progress to fibrosis, cirrhosis, liver failure, or hepatocellular carcinoma. Closely tied to the global obesity and diabetes epidemic, NASH has become a major healthcare burden, with millions affected worldwide and no widely approved curative therapy to date.
The NASH…
Non Alcoholic Steatohepatitis (NASH) Market Size to Hit $21,879 Million by 2028 …
According to our experience research team, Non Alcoholic Steatohepatitis (NASH) Market was valued at USD 1,569 Million in 2021, and the global Non Alcoholic Steatohepatitis (NASH) industry is projected to reach a value of USD 21,879 Million by 2028, at a CAGR of 60.4% during the forecast period 2022-2028
The report is focused on gaining various Non Alcoholic Steatohepatitis (NASH) market trends, dynamics, growth drivers, opportunities, weaknesses, strengths, and threats restraining…
NASH Market Insight and Landscape report
Report Snapshot:
NASH is one of the furthermost causes of liver disease worldwide and will probably emerge as the leading cause of end-stage liver disease in the coming years, with the disease affecting both adults and children. The epidemiology and demographic characteristics of NASH vary across different country level. Furthermore, individuals with NAFLD have a high frequency of metabolic comorbidities and could place a growing strain on health-care systems from their…
Nash releases debut EP 'She Don't Know'
London-based singer/songwriter Nash has released his debut EP She Don’t Know. Recorded at the legendary RAK Studios, She Don’t Know has the feel of 60s rock but with a modern twist, leaving the listener hooked throughout and wanting to come back for another listen. She Don’t Know’s leading single CK is an infectious number which is sure to be a hit for 2017.
Listening to the Beatles and Jack White growing…
Nash Technologies at GITEX/GULFCOMMS 2010
Harvey Nash subsidiary presents expert services to telecom operators in the Middle East, Africa and South Asia region
Nürnberg/Germany, 10th September 2010 – For the first time Nash Technologies will be present at GITEX/GULFCOMMS, the largest international trade event for mobile, fixed, IP and satellite communications for the Middle East, Africa and South Asia region, in Dubai from 17th to 21st October 2010 offering its telecom expert services. Nash Technologies will…
